Genomic Valley Biotech P/E Ratio
Current P/E Ratio
317.6
High Valuation
Very High - High growth expectations or significantly overvalued
Genomic Valley Biotech (GVBL) P/E ratio is 317.6 (High), EPS (TTM) ₹0.10, current price ₹29.00 on BSE — Very High - High growth expectations or significantly overvalued. For live price, revenue and the complete fundamental profile, see GVBL screener.
Current Valuation Metrics
P/E Ratio
317.6
Current Price
₹29.00
EPS (TTM)
₹0.10
Exchange
BSE
Valuation Signal
Signal
Overvalued
Sector Context
Sector Average
53.44
Sector Median
31.04
Sector Rank
#11 of 194
Sector Percentile
5.7%
GVBL P/E Ratio — Valuation Signal & Historical Context
Genomic Valley Biotech P/E 317.6 — signal: Overvalued. Read GVBL dividend payout details for the complete payout history and dividend yield track record.
- Stock appears overvalued with PE of 317.6, suggesting caution for new investments
- Trading at premium to sector average PE of 53.44
GVBL vs Healthcare Peers — P/E Ratio Comparison
Genomic Valley Biotech P/E 317.6 vs Healthcare average 53.44, median 31.04 — range 2.86–950.0.
Sector Average
53.44
Sector Median
31.04
Lowest P/E
2.86
Highest P/E
950.0
Companies
194
| Company | Symbol | P/E Ratio | Market Cap (₹ Cr) | Valuation |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | ₹41 | Low |
| Sunrest Lifescience | SUNREST | 3.65 | ₹29 | Low |
| Phaarmasia | PHRMASI | 3.89 | ₹69 | Low |
| JFL Life Sciences | JFLLIFE | 4.64 | ₹59 | Low |
| Sun Pharma Advanced Rese… | SPARC | 4.69 | ₹7,502 | Low |
| Shelter Pharma | SHELTER | 5.32 | ₹50 | Low |
| Mono Pharmacare | MONOPHARMA | 6.02 | ₹19 | Low |
| Royal Sense | ROYAL | 7.4 | ₹51 | Low |
| Zenith Drugs | ZENITHDRUG | 7.69 | ₹79 | Low |
| Amwill Health Care | AMWILL | 7.71 | ₹88 | Low |